RXC004

DRUG3 trials

Sponsors

Redx Pharma Ltd

Conditions

Advanced Solid TumoursCancerColorectal CancerSolid Tumor

Phase 1

Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies

CompletedNCT03447470

Redx Pharma LtdCancer, Solid Tumor

Start: 2019-03-18End: 2023-09-29Updated: 2025-01-29

Phase 2

A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)

CompletedNCT04907539

Redx Pharma LtdColorectal Cancer

Start: 2021-11-08End: 2024-04-02Updated: 2025-04-16

A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)

CompletedNCT04907851

Redx Pharma LtdAdvanced Solid Tumours

Start: 2021-12-10End: 2023-11-30Updated: 2025-03-17

Related Papers

A phase I dose-escalation study of LRP5/6 antagonist BI 905677 in patients with advanced solid tumors.

2024-11-014 citations

Abstract CT101: Final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumors

Cancer Research2024-04-052 citations

Abstract 1654: Pre-clinical activity of the Wnt/Beta-catenin pathway inhibitor RXC004 in models of biliary tract cancer

Cancer Research2023-04-04

719 Phase 1 study of the porcupine (PORCN) inhibitor RXC004 in combination with the PD-1 inhibitor nivolumab in patients with advanced solid tumors

Regular and Young Investigator Award Abstracts2022-11-012 citations

1455 Effective co-targeting of fibrotic and immune microenvironments to improve the overall anti-tumour response in models of advanced pancreatic cancer

Regular and Young Investigator Award Abstracts2022-11-01

Abstract 2566: Pre-clinical efficacy of the Wnt pathway inhibitor RXC004 in combination with anti-cancer therapies

Cancer Research2022-06-152 citations

A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments.

Journal of Clinical Oncology2022-06-018 citations

Abstract 998: Mechanism of action of RXC004, a Wnt pathway inhibitor, in genetically-defined models of cancer

Cancer Research2021-07-012 citations

Abstract 506: Wnt/â-Catenin pathway inhibitor RXC004 enhances the immunity of pre-clinical models of cancer

Cancer Research2019-07-0111 citations

Abstract 3874: Efficacy of the Wnt/Beta-Catenin pathway inhibitor RXC004 in genetically-defined models of cancer

Cancer Research2019-07-015 citations

Abstract 506: Wnt/â-Catenin pathway inhibitor RXC004 enhances the immunity of pre-clinical models of cancer

Immunology2019-07-01

Abstract 3874: Efficacy of the Wnt/Beta-Catenin pathway inhibitor RXC004 in genetically-defined models of cancer

Experimental and Molecular Therapeutics2019-07-01